Zynga Shares Drop as King Digital Gets Ready for IPO Filing; Twitter User Base Growth May be Slowing Down


Follow this company

Companies Mentioned

NYSE:TWTR / NASDAQ:ZNGA / NASDAQ:TSLA / NASDAQ:ASTM
03/25/2014 [ACCESSWIRE]

Twitter, Inc. (NYSE: TWTR) – For an in-depth report on Twitter, Inc. follow: www.BullTrends.com/stockquote/TWTR

Twitter shares closed down 4.22% on about 12.3 million shares traded. The stock was one of the leading decliners in the NYSE. The drop could be in response to a MotleyFool article from this past Friday that had said the company could be showing signals of a slowdown in user base growth.

Zynga, Inc. (NASDAQ: ZNGA) - For an in-depth report on Zynga, Inc. follow: www.BullTrends.com/stockquote/ZNGA

Shares of Zynga Inc. closed down about 5% on Monday with 34.4 million or so shares traded. The stock was one of the biggest decliners on the NASDAQ. The stock dropped on the news that King Digital, owner of number-one game app 'Candy Crush', will likely file for its IPO this week. King Digital is offering 15.5 million shares at a price between $21 and $24 a share. If it floats at the upper end of that range, its valuation of $7.6 billion would be nearly double Zynga's $4.11 billion market capitalization.

Tesla Motors, Inc. (NASDAQ: TSLA) - For an in-depth report on Tesla Motors, Inc. follow: www.BullTrends.com/stockquote/TSLA

TSLA shares closed down nearly 4% on Monday with about 11.3 million shares traded. The stock was one of the most active stocks on the NASDAQ. As of April 1, New Jersey is enforcing the law for every car company selling in the state to go through a dealership -- forcing Tesla to either cooperate or drop all New Jersey sales.

Aastrom Biosciences, Inc. (NASDAQ: ASTM) - For an in-depth report on Aastrom Biosciences, Inc. follow: www.BullTrends.com/stockquote/ASTM

Shares of ASTM closed down 21.73% on Monday making it one of the biggest decliners on the NASDAQ. The stock traded a little over 2 million shares compared to an average of about 300,000 shares. The leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announced earlier this month that Nick Colangelo, President and CEO of Aastrom, will present at the 2014 Regen Med Investor Day on Wednesday, March 26 at 3:15 p.m. EDT at the Metropolitan Club in New York City. 

 

Disclosure: BullTrends.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.

COMMENTS

Leave a comment...
 * 

Your Name
 *